KRAS as a druggable target in NSCLC: Rising like a phoenix after decades of development failures.
Sign Up to like & getrecommendations! Published in 2020 at "Cancer treatment reviews"
DOI: 10.1016/j.ctrv.2020.101978
Abstract: Cancers of nearly all lineages harbor alterations that deregulate mitogen-activated protein kinase signaling, a crucial signaling pathway for tumor formation and maintenance. Of these, KRAS mutations are the most frequent gain-of-function alterations found in patients… read more here.
Keywords: nsclc rising; target; kras druggable; druggable target ... See more keywords